Fortress Biotech Registers 600K Shares for Oaktree Resale

TL;DR

**Fortress Biotech's S-1 for Oaktree's 600,000 warrant shares signals potential dilution and selling pressure, making FBIO a cautious hold.**

AI Summary

Fortress Biotech, Inc. (FBIOP) filed an S-1 to register 600,000 shares of common stock for resale by selling stockholders, specifically Oaktree Fund Administration, LLC and its affiliates. These shares are issuable upon the exercise of warrants granted on December 12, 2025, with an exercise price of $2.62 per share. The company's common stock, FBIO, was trading at $2.94 per share on December 11, 2025. Fortress Biotech, a biopharmaceutical company, focuses on acquiring and advancing assets, generating revenue through product sales, equity holdings, and royalties. Recent strategic activities include the acquisition of Checkpoint Therapeutics, Inc. by Sun Pharma in May 2025, and Baergic Bio, Inc. by Axsome in November 2025. The company will not receive any proceeds from the resale of these 600,000 shares, but will bear all registration costs. As of December 11, 2025, Fortress Biotech had 31,037,937 shares of common stock outstanding.

Why It Matters

This S-1 filing signals a potential increase in the float of Fortress Biotech's common stock by 600,000 shares, representing approximately 1.9% of the current outstanding shares. For investors, this could introduce selling pressure if Oaktree and its affiliates decide to liquidate their holdings, potentially impacting FBIO's market price, which was $2.94 on December 11, 2025. The transaction stems from a credit agreement amendment, highlighting the company's ongoing financing strategies and its relationship with institutional lenders like Oaktree. Competitively, the biopharmaceutical sector is capital-intensive, and such warrant grants are common mechanisms for financing, but their subsequent registration for resale warrants investor attention.

Risk Assessment

Risk Level: medium — The registration of 600,000 shares for resale by selling stockholders, specifically Oaktree, introduces potential selling pressure on FBIO's stock. While the company will not receive proceeds, the increased float from 31,037,937 to 31,637,937 shares upon warrant exercise could dilute existing shareholder value and depress the stock price, especially given the exercise price of $2.62 is below the December 11, 2025 market price of $2.94.

Analyst Insight

Investors should monitor the trading activity of FBIO closely for signs of increased selling volume from Oaktree and its affiliates. Consider the potential impact of 600,000 additional shares entering the market on the stock's liquidity and price stability. Review Fortress Biotech's upcoming financial reports for any further financing activities or changes in its capital structure.

Key Numbers

• $2.94 — FBIO Stock Price (Last reported sale price on December 11, 2025, indicating market valuation.)
• $2.62 — Warrant Exercise Price (Price at which Oaktree can acquire shares, below current market price.)
• 600,000 — Shares Registered for Resale (Potential increase in market float from Oaktree's warrant exercise.)
• 31,037,937 — Shares Outstanding (Common stock outstanding as of December 11, 2025, before warrant exercise.)
• 31,637,937 — Shares Outstanding (Post-Warrant) (Total shares outstanding assuming full exercise of Oaktree's warrants.)
• December 12, 2025 — Warrant Grant Date (Date of the First Amendment to Credit Agreement and warrant issuance.)
• July 25, 2031 — Warrant Expiration Date (Long-term window for Oaktree to exercise its warrants.)
• May 2025 — Checkpoint Acquisition Date (Date Checkpoint Therapeutics was acquired by Sun Pharma.)
• November 2025 — Baergic Acquisition Date (Date Baergic Bio was acquired by Axsome Therapeutics.)

Key Players & Entities

• Fortress Biotech, Inc. (company) — Registrant and biopharmaceutical company
• Oaktree Fund Administration, LLC (company) — Recipient of warrants and selling stockholder
• Lindsay A. Rosenwald, M.D. (person) — Executive Chairman, CEO, and President of Fortress Biotech
• Troutman Pepper Locke LLP (company) — Legal counsel for Fortress Biotech
• SEC (regulator) — Securities and Exchange Commission
• Sun Pharma (company) — Acquired Checkpoint Therapeutics, Inc. in May 2025
• Axsome Therapeutics, Inc. (company) — Acquired Baergic Bio, Inc. in November 2025
• $2.94 (dollar_amount) — Last reported sale price of FBIO common stock on December 11, 2025
• $2.62 (dollar_amount) — Exercise price per share for the warrants granted to Oaktree
• 600,000 (dollar_amount) — Number of shares of common stock registered for resale

FAQ

Risk Factors

• Dilution from Warrants and Options [medium — financial]: As of December 11, 2025, there are 13,050,619 shares issuable upon exercise of outstanding warrants with a weighted average exercise price of $2.20, and 18,896 shares issuable upon exercise of stock options with a weighted average exercise price of $20.55. Additionally, 5,117,158 shares are underlying unvested Restricted Stock and RSUs. The exercise of these instruments could dilute existing shareholders' ownership.
• Market Price Volatility [high — market]: The company's business is influenced by many unpredictable factors, and uncertainties may materially affect actual results. Any material adverse effect on the business could lead to a decline in the market price of the Common Stock, potentially resulting in a loss for investors.
• Reliance on Incorporated Filings [medium — operational]: The risk factors for Fortress Biotech are primarily incorporated by reference from its most current Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Investors must rely on these prior filings and those of its partners (Journey, Mustang, and Avenue) for a comprehensive understanding of risks, which may not be fully up-to-date.

Industry Context

Fortress Biotech operates in the biopharmaceutical sector, focusing on acquiring and advancing clinical-stage assets. This strategy involves developing drug candidates through various stages, with potential revenue generated from product sales, equity holdings in partner companies, and royalties. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles, but also offers substantial rewards through successful drug development and market entry.

Regulatory Implications

As a biopharmaceutical company, Fortress Biotech is subject to stringent regulatory oversight by bodies like the FDA. The development and approval process for new drugs is lengthy and complex, with a high failure rate. Any delays or rejections in regulatory processes can significantly impact the company's financial performance and the value of its assets.

What Investors Should Do

1. Monitor warrant exercise and potential dilution.
2. Review incorporated risk factors.
3. Assess the company's asset advancement strategy.

Key Dates

• 2025-12-11: Shares outstanding reported — Provides a baseline for current equity structure before potential dilution from warrant exercises.
• 2025-12-12: Warrant grant date — Marks the issuance of warrants that are now being registered for resale, impacting potential future share count.
• 2025-05-01: Checkpoint Therapeutics acquisition by Sun Pharma — Represents a past strategic exit or partnership event for a Fortress Biotech asset, indicating the company's model of advancing and divesting assets.
• 2025-11-01: Baergic Bio, Inc. acquisition by Axsome — Another example of a successful asset advancement and acquisition, highlighting Fortress Biotech's strategy and potential for value creation.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. (This document is an S-1 filing, indicating Fortress Biotech is registering shares for resale by existing stockholders.)

Resale Prospectus

A prospectus that allows existing shareholders to sell their securities to the public without the company issuing new shares. (This S-1 is specifically for the resale of shares by Oaktree Fund Administration, LLC, not for raising new capital for Fortress Biotech.)

Selling Stockholders

Existing shareholders who are registering their shares for sale to the public. (Oaktree Fund Administration, LLC and its affiliates are the selling stockholders in this filing.)

Warrants

Financial instruments that give the holder the right, but not the obligation, to buy a company's stock at a specified price (exercise price) before a certain expiration date. (Oaktree holds warrants to purchase 600,000 shares of common stock at $2.62 per share.)

Shares Outstanding

The total number of shares of a company's stock that are currently held by all its shareholders, including share blocks held by institutions and company insiders. (As of December 11, 2025, there were 31,037,937 shares outstanding, providing context for potential dilution.)

Year-Over-Year Comparison

This S-1 filing focuses on the resale of shares by a specific stockholder (Oaktree) and does not appear to be a comprehensive update of the company's financial performance or strategic direction compared to a prior period. Key financial metrics such as revenue, net income, and margins are not detailed within this specific filing. The primary information provided relates to the structure of outstanding warrants and shares, and the company's business model of acquiring and advancing assets.

Key Financial Figures

• $0.001 — ”) of our common stock, par value $0.001 per share (“Common Stock”),
• $2.94 — rted sale price of our Common Stock was $2.94 per share. You are urged to obtain curr
• $2.62 — Stock at an exercise price per share of $2.62 (the “Warrants”). The Warra
• $20.55 — th a weighted average exercise price of $20.55 per share; and · 13,050,619 sh
• $2.20 — th a weighted average exercise price of $2.20 per share. Unless otherwise indicated

Filing Documents

• tm2533373d1_s1.htm (S-1) — 266KB
• tm2533373d1_ex4-10.htm (EX-4.10) — 81KB
• tm2533373d1_ex5-1.htm (EX-5.1) — 13KB
• tm2533373d1_ex10-27.htm (EX-10.27) — 736KB
• tm2533373d1_ex23-2.htm (EX-23.2) — 2KB
• tm2533373d1_ex-filingsfees.htm (EX-FILING FEES) — 25KB
• tm2533373d1_s1img001.jpg (GRAPHIC) — 7KB
• tm2533373d1_ex5-1img003.jpg (GRAPHIC) — 4KB
• image_001.gif (GRAPHIC) — 0KB
• 0001104659-25-121266.txt ( ) — 1258KB
• tm2533373d1_ex-filingsfees_htm.xml (XML) — 5KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS iii SUMMARY 1 THE OFFERING 3

USE OF PROCEEDS

USE OF PROCEEDS 4 DETERMINATION OF OFFERING PRICE 4 THE SELLING STOCKHOLDERS 5

DESCRIPTION OF SECURITIES BEING REGISTERED

DESCRIPTION OF SECURITIES BEING REGISTERED 7 CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS 9 PLAN OF DISTRIBUTION 15 LEGAL MATTERS 16 EXPERTS 16 WHERE YOU CAN FIND MORE INFORMATION 17 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 17 i ABOUT THIS PROSPECTUS This prospectus provides you with a general description of the shares of Common Stock that may be resold by the Selling Stockholders. In certain circumstances, we may provide a prospectus supplement that will contain specific information about the terms of a particular offering by the Selling Stockholders. We also may provide a prospectus supplement to add information to, or update or change information contained in, this prospectus. To the extent there is a conflict between the information contained in this prospectus and any prospectus supplement, you should rely on the information in the prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date — for example, a document incorporated by reference in this prospectus or any prospectus supplement — the statement in the later-dated document modifies or supersedes the earlier statement. You should read both this prospectus and any applicable prospectus supplement together with the additional information about our company to which we refer you in the sections of this prospectus titled “ Where You Can Find More Information ” and “ Incorporation of Certain Documents by Reference .” You should rely only on the information contained in or incorporated by reference into this prospectus and any prospectus supplement. Neither we nor the Selling Stockholders have authorized any dealer, salesperson or other person to provide you with different information. You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date other than the date o

Use of Proceeds

Use of Proceeds We will not receive any proceeds from the sale of the Resale Shares by the Selling Stockholders in this offering. See “ Use of Proceeds .”

Risk Factors

Risk Factors See “ Risk Factors ” incorporated by reference into this prospectus from our most current Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, for a discussion of certain factors you should carefully consider before deciding to invest in shares of our Common Stock. Nasdaq Capital Market Symbol FBIO (1)The number of shares of Common Stock is based on 31,037,937 shares of our Common Stock outstanding as of December 11, 2025, and excludes as of that date: · 5,117,158 shares of Common Stock underlying unvested Restricted Stock and Restricted Stock Units; · 18,896 shares of Common Stock issuable upon the exercise of stock options with a weighted average exercise price of $20.55 per share; and · 13,050,619 shares of Common Stock issuable upon exercise of outstanding warrants with a weighted average exercise price of $2.20 per share. Unless otherwise indicated, all information in this prospectus supplement assumes no exercise of the outstanding options or warrants or settlement of outstanding restricted stock units, described above. 3 RISK FACTORS Investing in our Common Stock involves a high degree of risk. Our business is influenced by many factors that are difficult to predict, involve uncertainties that may materially affect actual results and are often beyond our control. You should consider carefully the risks and uncertainties under the heading “ Risk Factors ” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and our Quarterly Reports for the fiscal periods ended March 31, 2025 , June 30, 2025 and September 30, 2025 , which are each incorporated by reference in this prospectus, and the risks, uncertainties and other information set forth in the reports and other materials filed or furnished by our partners and affiliates Journey, Mustang, and Avenue with the SEC, as well as any amendment or update to our risk factors in subsequent filings w

View Full Filing

View this S-1 filing on SEC EDGAR